Biological response modifiers in the treatment of malignant brain tumours: Role of interferons and retinoids

Joon H. Uhm, W. K.Alfred Yung

Research output: Contribution to journalArticle

Abstract

The retinoids and type I interferons constitute the 2 principal classes of biological response modifiers (BRMs) that have demonstrated activity in the treatment of malignant cerebral tumours, and are associated with fewer of the adverse effects induced by conventional chemotherapeutic agents. These BRMs share numerous common characteristics that may underlie their observed clinical efficacy. First, both classes of agent activate intracellular signal transduction pathways that, at numerous points, are capable of antagonising the oncogenic effects of growth factor-stimulated pathways in tumour cells. Secondly, the intracellular signals initiated by these BRMs ultimately lead to the activation of a multitude of genes; these genes, in turn, encode anti- tumourigenic functions that are distinct from the classic cytotoxic effects of conventional chemotherapeutic agents, such as the induction of differentiation and the inhibition of angiogenesis. Thirdly, while both classes of BRMs have demonstrated encouraging results in clinical trials when used as monotherapy, there is evidence that they may act synergistically when used in combination with each other or with conventional chemotherapeutic agents. With further refinements, the BRMs may develop into important adjunctive agents in the treatment of patients with malignant brain tumours.

Original languageEnglish (US)
Pages (from-to)11-24
Number of pages14
JournalCNS Drugs
Volume10
Issue number1
DOIs
StatePublished - 1998
Externally publishedYes

Fingerprint

Retinoids
Immunologic Factors
Brain Neoplasms
Interferons
Therapeutics
Interferon Type I
Genes
Signal Transduction
Neoplasms
Intercellular Signaling Peptides and Proteins
Clinical Trials

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health
  • Pharmacology (medical)

Cite this

Biological response modifiers in the treatment of malignant brain tumours : Role of interferons and retinoids. / Uhm, Joon H.; Yung, W. K.Alfred.

In: CNS Drugs, Vol. 10, No. 1, 1998, p. 11-24.

Research output: Contribution to journalArticle

@article{7087d0b6919841008c5a89e3126c9fc7,
title = "Biological response modifiers in the treatment of malignant brain tumours: Role of interferons and retinoids",
abstract = "The retinoids and type I interferons constitute the 2 principal classes of biological response modifiers (BRMs) that have demonstrated activity in the treatment of malignant cerebral tumours, and are associated with fewer of the adverse effects induced by conventional chemotherapeutic agents. These BRMs share numerous common characteristics that may underlie their observed clinical efficacy. First, both classes of agent activate intracellular signal transduction pathways that, at numerous points, are capable of antagonising the oncogenic effects of growth factor-stimulated pathways in tumour cells. Secondly, the intracellular signals initiated by these BRMs ultimately lead to the activation of a multitude of genes; these genes, in turn, encode anti- tumourigenic functions that are distinct from the classic cytotoxic effects of conventional chemotherapeutic agents, such as the induction of differentiation and the inhibition of angiogenesis. Thirdly, while both classes of BRMs have demonstrated encouraging results in clinical trials when used as monotherapy, there is evidence that they may act synergistically when used in combination with each other or with conventional chemotherapeutic agents. With further refinements, the BRMs may develop into important adjunctive agents in the treatment of patients with malignant brain tumours.",
author = "Uhm, {Joon H.} and Yung, {W. K.Alfred}",
year = "1998",
doi = "10.2165/00023210-199810010-00002",
language = "English (US)",
volume = "10",
pages = "11--24",
journal = "CNS Drugs",
issn = "1172-7047",
publisher = "Adis International Ltd",
number = "1",

}

TY - JOUR

T1 - Biological response modifiers in the treatment of malignant brain tumours

T2 - Role of interferons and retinoids

AU - Uhm, Joon H.

AU - Yung, W. K.Alfred

PY - 1998

Y1 - 1998

N2 - The retinoids and type I interferons constitute the 2 principal classes of biological response modifiers (BRMs) that have demonstrated activity in the treatment of malignant cerebral tumours, and are associated with fewer of the adverse effects induced by conventional chemotherapeutic agents. These BRMs share numerous common characteristics that may underlie their observed clinical efficacy. First, both classes of agent activate intracellular signal transduction pathways that, at numerous points, are capable of antagonising the oncogenic effects of growth factor-stimulated pathways in tumour cells. Secondly, the intracellular signals initiated by these BRMs ultimately lead to the activation of a multitude of genes; these genes, in turn, encode anti- tumourigenic functions that are distinct from the classic cytotoxic effects of conventional chemotherapeutic agents, such as the induction of differentiation and the inhibition of angiogenesis. Thirdly, while both classes of BRMs have demonstrated encouraging results in clinical trials when used as monotherapy, there is evidence that they may act synergistically when used in combination with each other or with conventional chemotherapeutic agents. With further refinements, the BRMs may develop into important adjunctive agents in the treatment of patients with malignant brain tumours.

AB - The retinoids and type I interferons constitute the 2 principal classes of biological response modifiers (BRMs) that have demonstrated activity in the treatment of malignant cerebral tumours, and are associated with fewer of the adverse effects induced by conventional chemotherapeutic agents. These BRMs share numerous common characteristics that may underlie their observed clinical efficacy. First, both classes of agent activate intracellular signal transduction pathways that, at numerous points, are capable of antagonising the oncogenic effects of growth factor-stimulated pathways in tumour cells. Secondly, the intracellular signals initiated by these BRMs ultimately lead to the activation of a multitude of genes; these genes, in turn, encode anti- tumourigenic functions that are distinct from the classic cytotoxic effects of conventional chemotherapeutic agents, such as the induction of differentiation and the inhibition of angiogenesis. Thirdly, while both classes of BRMs have demonstrated encouraging results in clinical trials when used as monotherapy, there is evidence that they may act synergistically when used in combination with each other or with conventional chemotherapeutic agents. With further refinements, the BRMs may develop into important adjunctive agents in the treatment of patients with malignant brain tumours.

UR - http://www.scopus.com/inward/record.url?scp=0031814312&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031814312&partnerID=8YFLogxK

U2 - 10.2165/00023210-199810010-00002

DO - 10.2165/00023210-199810010-00002

M3 - Article

AN - SCOPUS:0031814312

VL - 10

SP - 11

EP - 24

JO - CNS Drugs

JF - CNS Drugs

SN - 1172-7047

IS - 1

ER -